Clinical Trial Update: B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for a B7-H3–targeted autologous CAR-T cell therapy (3CAR) in pediatric solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Hepatoblastoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma
• Wilms Tumor

Drugs mentioned

• 3CAR (B7-H3-targeted autologous CAR-T cell therapy)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Pediatric Solid Tumor, Osteosarcoma | Phase 1 | Status: RECRUITING